Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Shares Outstanding (2016 - 2025)

Spyre Therapeutics' Shares Outstanding history spans 11 years, with the latest figure at $78.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 29.76% year-over-year to $78.2 million; the TTM value through Dec 2025 reached $78.2 million, up 29.76%, while the annual FY2025 figure was $78.2 million, 29.76% up from the prior year.
  • Shares Outstanding reached $78.2 million in Q4 2025 per SYRE's latest filing, up from $60.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $78.2 million in Q4 2025 to a low of $2.0 million in Q4 2021.
  • Average Shares Outstanding over 5 years is $33.2 million, with a median of $42.8 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding: plummeted 95.97% in 2022, then soared 1467.38% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $2.0 million in 2021, then skyrocketed by 32.42% to $2.6 million in 2022, then skyrocketed by 1279.38% to $36.1 million in 2023, then soared by 67.12% to $60.3 million in 2024, then increased by 29.76% to $78.2 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Shares Outstanding are $78.2 million (Q4 2025), $60.5 million (Q3 2025), and $60.4 million (Q2 2025).